nach oben

Erschienen in:

01.12.2013

Antihyperalgesic and Anti-inflammatory Effects of Atorvastatin in Chronic Constriction Injury-Induced Neuropathic Pain in Rats

verfasst von: Nitya N. Pathak, Venkanna Balaganur, Madhu C. Lingaraju, Amar S. More, Vinay Kant, Dhirendra Kumar, Dinesh Kumar, Surendra Kumar Tandan

Erschienen in: Inflammation | Ausgabe 6/2013

Einloggen, um Zugang zu erhalten

Abstract

Atorvastatin is a 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitor used in treatment of hypercholesterolemia and prevention of coronary heart disease. The aim of this study is to investigate the antihyperalgesic and anti-inflammatory effects of atorvastatin (3, 10, and 30 mg/kg by oral gavages for 14 days) in chronic constriction injury (CCI) model of neuropathic pain in rats. CCI caused significant increase in tumor necrosis factor-α, interleukin 1 beta, prostaglandin E2, along with matrix metalloproteases (MMP-2) and nerve growth factor (NGF) levels in sciatic nerve and spinal cord concomitant with mechanical and thermal hyperalgesia, which were significantly reduced by oral administration of atorvastatin for 14 days as compared to CCI rats. Our study demonstrated that atorvastatin attenuates neuropathic pain through inhibition of cytokines, MMP-2, and NGF in sciatic nerve and spinal cord suggesting that atorvastatin could be an additional therapeutic strategy in management of neuropathic pain.

Shamash, S., and S. Rotshenker. 2002. The cytokine network of Wallerian degeneration: tumor necrosis factor-α, interleukin-1α, and interleukin-1β. Journal of Neuroscience 22: 3052–3060.PubMed

Lee, H.L., K.M. Lee, S.J. Son, S.H. Hwang, and H.J. Cho. 2004. Temporal expression of cytokines and their receptors mRNAs in a neuropathic pain model. Neuroreport 15: 2807–2811.PubMed

Horai, R., S. Saijo, H. Tanioka, S. Nakae, K. Sudo, A. Okahara, T. Ikuse, M. Asano, and Y. Iwakura. 2000. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. The Journal of Experimental Medicine 191: 313–20.PubMedCrossRef

Lindholm, D., R. Heumann, M. Meyer, and H. Thoenem. 1987. Interleukin-1 regulates synthesis of nerve growth factor in non-neuronal cells of rat sciatic nerve. Nature 330: 658–659.PubMedCrossRef

Kawasaki, Y., Z.Z. Xu, X. Wang, J.Y. Park, Z.Y. Zhuang, P.H. Tan, Y.J. Gao, K. Roy, G. Corfas, E.H. Lo, and R.R. Ji. 2008. Distinct roles of matrix metalloproteases in the early- and late-phase development of neuropathic pain. Nature Medicine 14: 331–336.PubMedCrossRef

Yamaguchi, M., V. Jadhav, A. Obenaus, A. Colohan, and J.H. Zhang. 2007. Matrix metalloproteinase inhibition attenuates brain edema in an in vivo model of surgically-induced brain injury. Neurosurgery 61: 1067–75.PubMedCrossRef

Wang, Y., X.L. Deng, X.H. Xiao, and B.X. Yuan. 2007. A non-steroidal anti-inflammatory agent provides significant protection during focal ischemic stroke with decreased expression of matrix metalloproteinases. Current Neurovascular Research 4: 176–183.PubMedCrossRef

Bonnington, J.K., and P.A. McNaughton. 2003. Signaling pathways involved in the sensitization of mouse nociceptive neurons by nerve growth factor. The Journal of Physiology 551: 433–46.PubMedCrossRef

Gandhi, R., J.M. Ryals, and E. Douglas Wright. 2004. Neurotrophin-3 reverses chronic mechanical hyperalgesia induced by intramuscular acid injection. Journal of Neuroscience 24: 9405–9413.PubMedCrossRef

10.

Ryschich, E., V. Kerkadze, O. Deduchovas, O. Salnikova, A. Parseliunas, A. Märten, W. Hartwig, M. Sperandio, and J. Schmidt. 2009. Intracapillary leukocyte accumulation as a novel antihemorrhagic mechanism in acute pancreatitis in mice. Gut 23: 243–254.

11.

Smaldone, C., S. Brugaletta, V. Pazzano, and G. Liuzzo. 2009. Immunomodulator activity of 3-hydroxy-3-methilglutaryl-CoA inhibitors. Cardiovascular & Hematological Agents in Medicinal Chemistry 7: 279–294.CrossRef

12.

Etminan, M., A. Samii, and J.M. Brophy. 2010. Statin use and risk of epilepsy. Neurology 75: 1496–1500.PubMedCrossRef

13.

Naval, N.S., M.A. Mirski, and J.R. Carhuapoma. 2009. Impact of statins on validation of ICH mortality prediction models. Neurological Research 31: 425–429.PubMedCrossRef

14.

Bösel, J., F. Gandor, C. Harms, M. Synowitz, U. Harms, P.C. Djoufack, D. Megow, U. Dirnagl, H. Hortnagl, K.B. Fink, and M. Endres. 2005. Neuroprotective effects of atorvastatin against glutamate-induced excitotoxicity in primary cortical neurons. Journal of Neurochemistry 92: 1386–1398.PubMedCrossRef

15.

Sierra, S., M.C. Ramos, P. Molina, J.A. Vazquez, and J.S. Burgos. 2011. Statins as neuroprotectants: a comparative in vivo study of lipophilicity, blood–brain-barrier penetration, lowering of brain cholesterol, and decrease of neuron cell death. Journal of Alzheimer's Disease 23: 307–318.PubMed

16.

Van der Most, P.J., A.M. Dolga, I.M. Nijholt, P.G. Luiten, and U.L. Eisel. 2009. Statins: mechanisms of neuroprotection. Progress in Neurobiology 88: 64–75.PubMedCrossRef

17.

Wu, H., D. Lu, H. Jiang, Y. Xiong, C. Qu, B. Li, A. Mahmood, D. Zhou, and M. Chopp. 2008. Simvastatin-mediated upregulation of VEGF and BDNF, activation of the PI3K/Akt pathway and increase of neurogenesis are associated with therapeutic improvement after traumatic brain injury. Journal of Neurotrauma 25: 130–139.PubMedCrossRef

18.

Yang, D., Y. Han, J. Zhang, M. Chopp, and D.M. Seyfried. 2012. Statins enhance expression of growth factors and activate the PI3K/Akt-mediated signaling pathway after experimental intracerebral hemorrhage. World Journal of Neuroscience. 2: 74–80.PubMedCrossRef

19.

Tartakover-Matalon, S., N. Cherepnin, M. Kuchuk, L. Drucker, I. Kenis, A. Fishman, M. Pomeranz, and M. Lishner. 2007. Impaired migration of trophoblast cells caused by simvastatin is associated with decreased membrane IGF-I receptor, MMP2 activity and HSP27 expression. Human Reproduction 22: 1161–1167.PubMedCrossRef

20.

Massaro, M., A. Zampolli, E. Scoditti, M.A. Carluccio, C. Storelli, A. Distante, and R.D. Caterina. 2010. Statins inhibit cyclooxygenase-2 and matrix metalloproteinase-9 in human endothelial cells: anti-angiogenic actions possibly contributing to plaque stability. Cardiovascular Research 86: 311–320.PubMedCrossRef

21.

Pan, H.C., D.Y. Yang, Y.C. Ou, S.P. Ho, F.C. Cheng, and C.J. Chen. 2010. Neuroprotective effect of atorvastatin in an experimental model of nerve crush injury. Neurosurgery 67: 376–389.PubMedCrossRef

22.

Shi, X.Q., T.K.Y. Lim, S. Lee, Y.Q. Zhao, and J. Zhang. 2011. Statins alleviate experimental nerve injury-induced neuropathic pain. Pain 152: 1033–1043.PubMedCrossRef

23.

Chu, L.W., J.Y. Chen, K.L. Yu, K.I. Cheng, P.C. Wu, and B.N. Wu. 2012. Neuroprotective and anti-inflammatory activities of atorvastatin in a rat chronic constriction injury model. International Journal of Immunopathology and Pharmacology 25: 219–30.PubMed

24.

Bennett, G., and Y. Xie. 1988. A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain 33: 87–107.PubMedCrossRef

25.

Randall, L.O., and J. Selitto. 1957. A method for measurement of analgesic activity of inflamed tissue. Archives Internationales de Pharmacodynamie et de Therapie 111: 209–219.

26.

Hargreaves, K., R. Dubner, F. Brown, C. Flores, and J. Joris. 1988. A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 32: 77–88.PubMedCrossRef

27.

Youssef, S., O. Stuve, J.C. Patarroyo, P.J. Ruiz, J.L. Radosevich, E.M. Hur, M. Bravo, D.J. Mitchell, R.A. Sobel, L. Steinman, and S.S. Zamvil. 2002. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 420: 78–84.PubMedCrossRef

28.

Stepien, K., M. Tomaszewski, and S.J. Czuczwar. 2005. Neuroprotective properties of statins. Pharmacological Reports 57: 561–569.PubMed

29.

Muthuraman, A., and N. Singh. 2012. Neuroprotective effect of saponin rich extract of Acorus calamus L. in rat model of chronic constriction injury (CCI) of sciatic nerve-induced neuropathic pain. Journal of Ethnopharmacology 142: 723–731.PubMedCrossRef

30.

Chen, Y.W., Y.T. Li, Y.C. Chen, Z.Y. Li, and C.H. Hung. 2012. Exercise training attenuates neuropathic pain and cytokine expression following chronic constriction injury of rat sciatic nerve. Anesthesia and Analgesia 114: 1330–7.PubMedCrossRef

31.

Sacerdote, P., S. Franchi, S. Moretti, M. Castelli, P. Procacci, V. Magnaghi, and A.E. Panerai. 2013. Cytokine modulation is necessary for efficacious treatment of experimental neuropathic pain. Journal of Neuroimmune Pharmacology 8: 202–211.PubMedCrossRef

32.

Zelenka, M., M. Schafers, and C. Sommer. 2005. Intraneural injection of interleukin-1beta and tumor necrosis factor-alpha into rat sciatic nerve at physiological doses induces signs of neuropathic pain. Pain 116: 257–263.PubMedCrossRef

33.

Hao, S., M. Mata, J.C. Glorioso, and D.J. Fink. 2006. HSV-mediated expression of interleukin-4 in dorsal root ganglion neurons reduces neuropathic pain. Molecular Pain 2: 6.PubMedCrossRef

34.

Schafers, M., and C. Sommer. 2007. Anticytokine therapy in neuropathic pain management. Expert Review of Neurotherapeutics 7: 1613–27.PubMedCrossRef

35.

Sommer, C., J.A. Galbraith, H.M. Heckman, and R.R. Myers. 1993. Pathology of experimental compression neuropathy producing hyperesthesia. Journal of Neuropathology and Experimental Neurology 52: 223–233.PubMedCrossRef

36.

Sommer, C., and M. Kress. 2004. Recent findings on how proinflammatory cytokines cause pain: peripheral mechanisms in inflammatory and neuropathic hyperalgesia. Neuroscience Letters 361: 184–187.PubMedCrossRef

37.

Uceyler, N., and C. Sommer. 2008. Cytokine regulation in animal models of neuropathic pain and in human diseases. Neuroscience Letters 437: 194–198.PubMedCrossRef

38.

Samad, T.A., K.A. Moore, A. Sapirstein, S. Billet, A. Allchorne, S. Poole, J.V. Bonventre, and C.J. Woolf. 2001. Interleukin-1beta-mediated induction of Cox-2 in the CNS contributes to inflammatory pain hypersensitivity. Nature 410: 471–5.PubMedCrossRef

39.

Moolwaney, A.S., and O.J. Igwe. 2005. Regulation of the cyclooxygenase-2 system by interleukin-1 beta through mitogen-activated protein kinase signaling pathways: a comparative study of human neuroglioma and neuroblastoma cells. Brain Research. Molecular Brain Research 137: 202–212.PubMedCrossRef

40.

Wagner, R., and R.R. Myers. 1996. Endoneurial injection of TNF-alpha produces neuropathic pain behaviors. Neuroreport 7: 2897–2901.PubMedCrossRef

41.

Muja, N., and G.H. DeVries. 2004. Prostaglandin E2 and 6-keto-prostaglandin F (1alpha) production is elevated following traumatic injury to sciatic nerve. GLIA 46: 116–129.PubMedCrossRef

42.

Yaksh, T.L., D.M. Dirig, C.M. Conway, C. Svensson, Z.D. Luo, and P.C. Isakson. 2001. The acute antihyperalgesic action of nonsteroidal, anti-inflammatory drugs and release of spinal prostaglandin E2 is mediated by the inhibition of constitutive spinal cyclooxygenase-2 (COX-2) but not COX-1. Journal of Neuroscience 21: 5847–5853.PubMed

43.

Takahashi, M., M. Kawaguchi, K. Shimada, N. Konishi, H. Furuya, and T. Nakashima. 2004. Cyclooxygenase-2 expression in Schwann cells and macrophages in the sciatic nerve after single spinal nerve injury in rats. Neuroscience Letters 363: 203–206.PubMedCrossRef

44.

Durrenberger, P.F., P. Facer, M.A. Casula, Y. Yiangoul, R.A. Gray, I.P. Chessell, N.C. Day, S.D. Collins, S. Bingham, A.W. Wilson, D. Elliot, R. Birch, and P. Anand. 2006. Prostanoid receptor EP1 and Cox-2 in injured human nerves and a rat model of nerve injury: a time-course study. BMC Neurology 6: 1–11.PubMedCrossRef

45.

Schönbeck, U., and P. Libby. 2004. Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents? Circulation 109: 18–26.CrossRef

46.

Santodomingo-Garzon, T., T.M. Cunha, W.A. Verri, D.A. Valerio, C.A. Parada, S. Poole, S.H. Ferreira, and F.Q. Cunha. 2006. Atorvastatin inhibits inflammatory hypernociception. British Journal of Pharmacology 149: 14–22.PubMedCrossRef

47.

Planavila, A., J.C. Laguna, and M. Vazquez-Carrera. 2005. Atorvastatin improves peroxisome proliferator-activated receptor signaling in cardiac hypertrophy by preventing nuclear factor-kappa B activation. Biochimica et Biophysica Acta 1687: 76–83.PubMedCrossRef

48.

Prasad, R., S. Giri, N. Nath, I. Singh, and A.K. Singh. 2005. Inhibition of phosphoinositide 3 kinase-Akt (protein kinase B)-nuclear factor-kappa B pathway by lovastatin limits endothelial-monocyte cell interaction. Journal of Neurochemistry 94: 204–214.PubMedCrossRef

49.

Ali, S., and D.A. Mann. 2004. Signal transduction via the NF-kappa pathway: a targeted treatment modality for infection, inflammation and repair. Cell Biochemistry and Function 22: 67–79.PubMedCrossRef

50.

Wu, K.K. 2005. Control of cyclooxygenase-2 transcriptional activation by pro-inflammatory mediators. Prostaglandins, Leukotrienes, and Essential Fatty Acids 72: 89–93.PubMedCrossRef

51.

Digicaylioglu, M., and S.A. Lipton. 2001. Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades. Nature 412: 641–647.PubMedCrossRef

52.

Cain, J.H., C. Baggott, J.I. Tilghman, S. Rajpal, G.S. Miranpuri, and D.K. Resnick. 2007. Recent developments in the study of spinal cord injury and neuropathic pain. Annals of Neuroscience. 14: 96–107.CrossRef

53.

Folguerasa, A.R., T. Valdés-Sánchezb, E. Llanoa, L. Menéndezc, A. Baamondec, B.L. Denlingerd, C. Belmonted, L. Juárezc, A. Lastrac, O. García-Suáreze, A. Astudilloe, M. Kirsteinb, A.M. Pendása, I. Fariñasb, and C. López-Otína. 2009. Metalloproteinase MT5-MMP is an essential modulator of neuroimmune interactions in thermal pain stimulation. Proceedings of the National Academy of Sciences of the United States of America 106: 16451–16456.CrossRef

54.

Agrawal, S.M., L. Lau, and V.W. Yong. 2008. MMPs in the central nervous system: where the good guys go bad. Seminars in Cell & Developmental Biology 19: 42–51.CrossRef

55.

Buss, A., K. Pech, B.A. Kakulas, D. Martin, J. Schoenen, J. Noth, and G.A. Brook. 2007. Matrix metalloproteinases and their inhibitors in human traumatic spinal cord injury. BMC Neurology 7: 17.PubMedCrossRef

56.

Hsu, J., R. McKeon, S. Goussev, Z. Werb, J.U. Lee, A. Trivedi, and L. Noble-Haeusslein. 2006. Matrix metalloproteinase-2 facilitates wound healing events that promote functional recovery after spinal cord injury. Journal of Neuroscience 26: 9841–9850.PubMedCrossRef

57.

Ji, R.R., Z.Z. Xu, X. Wang, and E.H. Lo. 2009. Matrix metalloproteases regulation of neuropathic pain. Trends in Pharmacological Sciences 30: 336–340.PubMedCrossRef

58.

Sommer, C., C. Schmidt, A. George, and K.V. Toyka. 1997. A metalloprotease-inhibitor reduces pain associated behavior in mice with experimental neuropathy. Neuroscience Letters 237: 45–48.PubMedCrossRef

59.

Dray, A. 2008. Neuropathic pain: emerging treatments. British Journal of Anaesthesia 101: 48–58.PubMedCrossRef

60.

Lewin, G.R., A.M. Ritter, and L.M. Mendell. 1993. Nerve growth factor-induced hyperalgesia in the neonatal and adult rat. Journal of Neuroscience 13: 2136–2148.PubMed

61.

Petty, B.G., D.R. Cornblath, B.T. Adornato, V. Chaudhry, C. Flexner, M. Wachsman, D. Sinicropi, L.E. Burton, and S.J. Perouka. 1994. The effect of systematically administered recombinant human nerve growth factor in healthy subjects. Annals of Neurology 36: 244–246.PubMedCrossRef

62.

Ramer, M.S., M.D. Kawaja, J.T. Henderson, J.C. Roder, and M.A. Bisby. 1998. Glial overexpression of NGF enhances neuropathic pain and adrenergic sprouting into DRG following chronic sciatic constriction in mice. Neuroscience Letters 251: 53–6.PubMedCrossRef

63.

Lewin, G.R., A. Rueff, and L.M. Mendell. 1994. Peripheral and central mechanisms of NGF-induced hyperalgesia. European Journal of Neuroscience 6: 1903–1912.PubMedCrossRef

64.

Hao, J., T. Ebendal, X. Xu, Z. Wiesenfeld-Hallin, and M. Eriksdotter Jönhagen. 2000. Intracerebroventricular infusion of nerve growth factor induces pain-like response in rats. Neuroscience Letters 286: 208–212.PubMedCrossRef

65.

Herzberg, U., E. Eliav, J.M. Dorsey, R.H. Gracely, and I.J. Kopin. 1997. NGF involvement in pain induced by chronic constriction injury of the rat sciatic nerve. Neuroreport 8: 1613–1618.PubMedCrossRef

66.

Fukuoka, T., E. Kondo, Y. Dai, N. Hashimoto, and K. Noguchi. 2001. Brain-derived neurotrophic factor increases in the uninjured dorsal root ganglion neurons in selective spinal nerve ligation model. Journal of Neuroscience 21: 4891–900.PubMed

67.

Gwak, Y.S., T.S. Nam, K.S. Paik, C.E. Hulsebosch, and J.W. Leem. 2003. Attenuation of mechanical hyperalgesia following spinal cord injury by administration of antibodies to nerve growth factor in the rat. Neuroscience Letters 336: 117–120.PubMedCrossRef

68.

Paul, S. 2009. News and analysis, an audience with---Nature Reviews Drug Discovery 8: 14.PubMedCrossRef

69.

Spranger, M., D. Lindholm, C. Bandtlow, R. Heumann, H. Gnahn, M. Nlher-Noe, and H. Thoenen. 1990. Regulation of nerve growth factor (NGF) synthesis in the rat central nervous system: comparison between the effects of interleukin-1 and various growth factors in astrocyte cultures and in vivo. European Journal of Neuroscience 2: 69–16.PubMedCrossRef

70.

Wang, H., J.R. Lynch, P. Song, H.J. Yang, R.B. Yates, B. Mace, D.S. Warner, J.R. Guyton, and D.T. Laskowitz. 2007. Simvastatin and atorvastatin improve behavioral outcome, reduce hippocampal degeneration, and improve cerebral blood flow after experimental traumatic brain injury. Experimental Neurology 206: 59–69.PubMedCrossRef

71.

Gholami, M.R., F. Abolhassani, P. Pasbakhsh, M. Akbari, A. Sobhani, M.R. Eshraghian, N. Kamalian, F.A. Amoli, A.R. Dehpoor, and D. Sohrabi. 2008. The effects of simvastatin on ischemia-reperfusion injury of sciatic nerve in adult rats. European Journal of Pharmacology 590: 111–114.PubMedCrossRef

72.

Chen, G., S. Zhang, J. Shi, J. Ai, M. Qi, and C. Hang. 2009. Simvastatin reduces secondary brain injury caused by cortical contusion in rats: possible involvement of TLR4/NF-κB pathway. Experimental Neurology 216: 398–406.PubMedCrossRef

73.

Laufs, U., K. Gertz, P. Huang, G. Nickenig, M. Bohm, U. Dirnagl, and M. Endres. 2000. Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice. Stroke 31: 2442–2449.PubMedCrossRef

74.

Amarenco, P., J. Bogousslavsky, A. Callahan, L.B. Goldstein, M. Hennerici, A.E. Rudolph, H. Sillesen, L. Simunovic, M. Szarek, K.M. Welch, and J.A. Zivin. 2006. High-dose atorvastatin after stroke or transient ischemic attack. The New England Journal of Medicine 355: 549–559.PubMedCrossRef

75.

Barsantea, M.M., E. Roffe, C.M. Yokorob, W.L. Tafuric, D.G. Souzab, V. Pinhoa, M.S. Castrob, and M.M. Teixeira. 2005. Anti-inflammatory and analgesic effects of atorvastatin in a rat model of adjuvant-induced arthritis. European Journal of Pharmacology 516: 282–289.CrossRef

76.

Weis, M., C. Heeschen, A.J. Glassford, and J.P. Cooke. 2002. Statins have biphasic effects on angiogenesis. Circulation 105: 739–45.PubMedCrossRef

77.

McMahon, S.B., W.B. Cafferty, and F. Marchand. 2005. Immune and glial cell factors as pain mediators and modulators. Experimental Neurology 192: 444–462.PubMedCrossRef

78.

Watkins, L.R., and S.F. Maier. 2002. Beyond neurons: evidence that immune and glial cells contribute to pathological pain states. Physiological Reviews 82: 981–1011.PubMed

79.

Mika, J., M. Osikowicz, E. Rojewska, M. Korostynski, A. Wawrzczak-Bargiela, R. Przewlocki, and B. Przewlocka. 2009. Differential activation of spinal microglial and astroglial cells in a mouse model of peripheral neuropathic pain. European Journal of Pharmacology 623: 65–72.PubMedCrossRef

80.

Zhang, J., and Y. de Koninck. 2009. Central neuroglial interactions in the pathophysiology of neuropathic pain. In Functional pain syndromes: presentation and pathophysiology, ed. E.A. Mayer and M.C. Bushnell, 319–336. Seattle, WA: IASP Press.

81.

Clarke, R.M., F. O'Connell, A. Lyons, and M.A. Lynch. 2007. The HMG-CoA reductase inhibitor, atorvastatin, attenuates the effects of acute administration of amyloid-beta1–42 in the rat hippocampus in vivo. Neuropharmacology 52: 136–145.PubMedCrossRef

82.

Li, B., A. Mahmood, D. Lu, H. Wu, Y. Xiong, C. Qu, and M. Chopp. 2009. Simvastatin attenuates microglial cells and astrocyte activation and decreases interleukin-1beta level after traumatic brain injury. Neurosurgery 65: 179–185.PubMedCrossRef

83.

Wu, H., A. Mahmood, D. Lu, H. Jiang, Y. Xiong, D. Zhou, and M. Chopp. 2009. Attenuation of astrogliosis and modulation of endothelial growth factor receptor in lipid rafts by simvastatin after traumatic brain injury. Journal of Neurosurgery 113: 591–597.CrossRef

Titel: Antihyperalgesic and Anti-inflammatory Effects of Atorvastatin in Chronic Constriction Injury-Induced Neuropathic Pain in Rats
verfasst von: Nitya N. Pathak
Venkanna Balaganur
Madhu C. Lingaraju
Amar S. More
Vinay Kant
Dhirendra Kumar
Dinesh Kumar
Surendra Kumar Tandan
Publikationsdatum: 01.12.2013
Verlag: Springer US
Erschienen in: Inflammation / Ausgabe 6/2013
Print ISSN: 0360-3997
Elektronische ISSN: 1573-2576
DOI: https://doi.org/10.1007/s10753-013-9688-x

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern. Das lassen retrospektive Daten vermuten.

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Wie der Klimawandel gefährliche Pilzinfektionen begünstigt

24.05.2024 Candida-Mykosen Nachrichten

Dass sich invasive Pilzinfektionen in letzter Zeit weltweit häufen, liegt wahrscheinlich auch am Klimawandel. Ausbrüche mit dem Hefepilz Candida auris stellen eine zunehmende Gefahr für Immungeschwächte dar – auch in Deutschland.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2013

Anti-Inflammatory Effect of Auraptene Extracted from Trifoliate Orange (Poncirus Trifoliate) on LPS-Stimulated RAW 264.7 Cells

5-Lipoxygenase Inhibitor Zileuton Inhibits Neuronal Apoptosis Following Focal Cerebral Ischemia

Comparison of α2-Macroglobulin Synthesis by Juvenile vs. Mature Rats after Identical Inflammatory Stimulation

Formononetin Inhibited the Inflammation of LPS-Induced Acute Lung Injury in Mice Associated with Induction of PPAR Gamma Expression

Comparison of the Effects of Desflurane and Propofol Anesthesia on the Inflammatory Response and S100β Protein During Coronary Artery Bypass Grafting